THNR - ETF AI Analysis
Top Page
Amplify Weight Loss Drug & Treatment ETF (THNR)
THNR’s rating suggests it is a reasonably solid but somewhat specialized ETF focused on weight loss drugs and related treatments, with its quality supported by large, established pharma leaders like AstraZeneca, Amgen, Eli Lilly, Novo Nordisk, Roche, Pfizer, and AbbVie that bring strong financial performance, product pipelines, and generally positive outlooks. The fund’s weaker spots come from earlier-stage or less consistently profitable names like Viking Therapeutics and Innovent Biologics, which add growth potential but also higher risk. The main risk factor is the ETF’s concentration in a single, highly specialized healthcare niche, where valuation concerns, high leverage at some holdings, and competitive pressures could increase volatility.
THNR vs. SPDR S&P 500 ETF (SPY)
- AUM
- 5.76M
- Region
- Developed Markets
- Expense Ratio
- 0.59%
- Beta
- 0.64
- Issuer
- Amplify
- Inception Date
- May 21, 2024
- Dividend Yield
- 1.66%
- Asset Class
- Equity
- Index Tracked
- VettaFi Weight Loss Drug & Treatment Index - Benchmark TR Net
THNR Summary
The Amplify Weight Loss Drug & Treatment ETF (THNR) is a fund that follows the VettaFi Weight Loss Drug & Treatment Index and focuses on health care companies working on weight loss drugs and related treatments. It mainly holds pharmaceutical and biotech firms, including well-known names like Novo Nordisk and Eli Lilly, which make popular weight loss and diabetes medications. Someone might invest in this ETF to seek growth from the rising demand for obesity and weight management treatments and to get diversified exposure to many companies in this niche. A key risk is that it is heavily concentrated in health care and can rise or fall sharply with news about drug approvals, regulations, or medical breakthroughs.
How much will it cost me?
The Amplify Weight Loss Drug & Treatment ETF (THNR) has an expense ratio of 0.59%, meaning you’ll pay $5.90 per year for every $1,000 invested. This is higher than average for ETFs because it is actively managed and focuses on a specialized niche in the health care sector. Actively managed funds typically have higher costs due to the research and expertise required to select investments.
What would affect this ETF?
The Amplify Weight Loss Drug & Treatment ETF (THNR) could benefit from growing global awareness of obesity-related health issues and increased demand for innovative weight loss treatments, especially as its top holdings include major pharmaceutical companies like Eli Lilly and Novo Nordisk, which are leaders in this space. However, the ETF may face challenges from regulatory hurdles, competition in drug development, or economic downturns that could reduce consumer spending on health care solutions. Additionally, its heavy reliance on the health care sector makes it vulnerable to sector-specific risks, such as changes in government policies or patent expirations.
THNR Top 10 Holdings
THNR is essentially a bet on the global weight-loss and obesity-treatment boom, with Eli Lilly and Novo Nordisk acting as the main engines of the story—though Novo has been lagging lately, taking a bit of shine off the theme. Amgen and AbbVie add steady, rising support from the big pharma side, while Viking Therapeutics brings more volatile, early-stage biotech flavor that can swing results. With nearly all exposure in health care and a mix of U.S., European, and Hong Kong names, the fund is both thematically tight and geographically diversified.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co | 11.22% | $645.68K | $1.21T | 58.93% | 72Outperform |
 NVO | Novo Nordisk | 8.78% | $505.06K | $174.26B | -28.70% | 73Outperform |
 AMGN | Amgen | 6.01% | $345.88K | $236.98B | 45.56% | 77Outperform |
 ABBV | AbbVie | 5.77% | $332.15K | $510.84B | 23.08% | 66Neutral |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 PFE | Pfizer | 5.70% | $328.08K | $171.62B | 20.12% | 74Outperform |
 GILD | Gilead Sciences | 5.50% | $316.78K | $194.07B | 23.77% | 78Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 REGN | Regeneron | 5.33% | $306.84K | $83.13B | 39.07% | 78Outperform |
 HK:1093 | CSPC Pharmaceutical Group | 5.17% | $297.78K | HKD 102.61B | -2.47% | 63Neutral |
THNR Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For THNR, the sentiment is Neutral. The current price of 24.92 is above the 20-day moving average (MA) of 24.74, below the 50-day MA of 25.80, and below the 200-day MA of 25.36, indicating a neutral trend. The MACD of -0.29 indicates Negative momentum. The RSI at 48.92 is Neutral, neither overbought nor oversold. The STOCH value of 85.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for THNR.
THNR Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| THNR | $24.92 | $27.00(8.33% Upside) | $5.76M | 0.59% | 62Neutral |
 AGNG | $37.96 | $42.75(12.62% Upside) | $92.69M | 0.50% | 64Neutral |
 FDIQ | $74.23 | $85.01(14.52% Upside) | $41.92M | 0.35% | 73Outperform |
 WISE | $32.60 | $65.90(102.17% Upside) | $23.01M | 0.35% | 57Neutral |
 IVEP | $24.40 | $34.60(41.82% Upside) | $14.39M | 0.75% | 70Outperform |
 FOWF | $34.28 | $45.61(33.07% Upside) | $14.51M | 0.49% | 70Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| THNR | Amplify Weight Loss Drug & Treatment ETF | 24.92 | 2.13 | 9.36% | |
| AGNG | Global X Aging Population ETF | 37.95 | 4.18 | 12.39% | |
| FDIQ | Invesco Bloomberg Financial Data Providers ETF | 74.23 | 17.80 | 31.55% | |
| WISE | Themes Generative Artificial Intelligence ETF | 32.60 | -10.37 | -24.13% | |
| IVEP | Dan IVES Wedbush AI Power & Infrastructure ETF | 24.40 | -1.70 | -6.51% | |
| FOWF | Pacer Solactive Whitney Future of Warfare ETF | 34.27 | 2.96 | 9.45% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.